Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.65    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.05 (1.075%)
Market Cap: £223.18m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

Technical Paper Series - Intoxication launched

17 Dec 2025 07:00

RNS Number : 9169L
Seeing Machines Limited
17 December 2025
 

PRESS RELEASE

 

Seeing Machines Technical Paper Series on Non-Fatigue Impairment launched

Alcohol-related driver impairment remains a key factor in road accidents globally as current roadside strategies don't go far enough

Canberra, 17 December 2025: Seeing Machines Limited, a global leader in vision-based monitoring technology, has released Part One of its new Technical Paper series, dedicated to advancing the understanding and detection of non-fatigue driver impairment, starting with intoxication. This initiative marks a major step in the company's broader focus on leveraging its Driver Monitoring System (DMS) technology to address critical safety challenges on roads, globally.

Alcohol continues to be a leading cause of road trauma worldwide, contributing significantly to fatalities and injuries despite ongoing roadside based preventative efforts. Recognising these persistent risks, Seeing Machines has launched its capability to harness the power of DMS technology to identify impairment from alcohol in real time.

The Company's latest research highlights the limitations of relying solely on Blood Alcohol Concentration (BAC) as a benchmark for impairment. Traditional approaches often overlook the way impairment unfolds over time, resulting in gaps between BAC progression and real-world driver performance. Seeing Machines' DMS technology aims to bridge this divide by directly assessing functional impairment in real time, ensuring enhanced detection sensitivity and more effective in-cabin intervention strategies.

"Roadside alcohol testing has delivered great reductions in road injury over many years. Our goal is to complement these existing roadside programs by leading the introduction of in-vehicle approaches," said Dr Mike Lenné, Chief Safety Officer at Seeing Machines. "By incorporating the temporal dynamics of impairment, how it evolves during both the ascending and descending phases of intoxication from alcohol as well as the complex effects of other drugs such as cannabis, our technology can reflect real-time real-world risks and provide greater safety protections to road users."

To support this approach, Seeing Machines is working with leading experts and universities, conducting pioneering experiments that explore the disconnect between BAC readings and actual driver impairment. These collaborations underscore the Company's commitment to developing solutions that align technological innovation with real-world safety outcomes.

Part One of the Technical Paper series is now available, with future instalments set to explore additional aspects of non-fatigue impairment, including from cannabis, and further enhance the capabilities of DMS technology for road safety.

Click here for Part One: https://seeingmachines.com/technical-paper-series-intoxication

-ends-

About Seeing Machines (LSE: SEE)

Seeing Machines is a global company founded in 2000 and headquartered in Australia, is an industry leader in vision-based monitoring technology that enable machines to see, understand and assist people. Seeing Machines is revolutionising global transport safety. Its technology portfolio of AI algorithms, embedded processing and optics, power products that need to deliver reliable real-time understanding of vehicle operators. The technology spans the critical measurement of where a driver is looking, through to classification of their cognitive state as it applies to accident risk. Reliable "driver state" measurement is the end-goal of Driver Monitoring Systems (DMS) technology. Seeing Machines develops DMS technology to drive safety for Automotive, Commercial Fleet, Off-road and Aviation. The company has offices in Australia, USA, Europe and Asia, and supplies technology solutions and services to industry leaders in each market vertical. www.seeingmachines.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEDLBFELLZFBK
Date   Source Headline
20th Dec 20237:00 amRNSSeeing Machines announces US$30M European OEM win
13th Dec 20238:02 amRNSSeeing Machines welcomes U.S. NHTSA announcement
12th Dec 20237:00 amRNSSeeing Machines Wins Prestigious Road Safety Award
29th Nov 20237:57 amRNSResult of AGM
24th Nov 20237:00 amRNSAGM – reminder and correction of login details
8th Nov 20237:00 amRNS16th Automotive program awarded & Q1 FY2024 KPIs
6th Nov 202311:26 amRNSDirector/PDMR Shareholding
31st Oct 202311:50 amRNSDirector/PDMR Shareholding
31st Oct 20237:00 amRNSNotice of AGM
27th Oct 20237:19 amRNSDirector/PDMR Shareholding
27th Oct 20237:13 amRNSDirector/PDMR Shareholding
25th Oct 20237:55 amRNSDirector/PDMR Shareholding
25th Oct 20237:00 amRNSBoard Changes
20th Oct 20239:30 amRNSDirector/PDMR Shareholding
20th Oct 20239:21 amRNSDirector/PDMR Shareholding
19th Oct 20238:47 amRNSDirector/PDMR Shareholding
18th Oct 202310:06 amRNSDirector/PDMR Shareholding
17th Oct 20239:41 amRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSYear End Results – FY2023
16th Oct 20237:00 amRNSDevelopment of aviation fatigue detection solution
14th Sep 20237:00 amRNSNotice of Full Year Results 2023
7th Sep 20235:31 pmRNSDirector/PDMR Shareholding
22nd Aug 20237:00 amRNSFY2023 Trading Update & Q4 KPIs
18th Jul 20237:30 amRNSDirector/PDMR Shareholding
30th Jun 20237:00 amRNSDirector/PDMR Shareholding
30th Jun 20237:00 amRNSCEO Incentive Plan
28th Jun 20231:44 pmRNSDirector/PDMR Shareholding
28th Jun 20237:00 amRNSDirector/PDMR Shareholding
26th Jun 202311:38 amRNSDirector/PDMR Shareholding
23rd Jun 20238:55 amRNSDirector/PDMR Shareholding
20th Jun 20237:30 amRNSCollaboration with synthetic data specialist
19th Jun 20238:00 amRNSSeeing Machines to attend Stifel Tech Conference
25th May 20239:53 amRNSDirector/PDMR Shareholding
22nd May 20239:46 amRNSDirector/PDMR Shareholding
16th May 20237:00 amRNSExclusive Agreement Signed with Collins Aerospace
4th May 20237:00 amRNSKey Performance Indicators Q3 FY2023
17th Apr 20239:29 amRNSDirector/PDMR Shareholding
13th Apr 202312:36 pmRNSDirector/PDMR Shareholding
11th Apr 202311:15 amRNSPDMR Shareholding
6th Apr 20232:45 pmRNSDirector/PDMR Shareholding
5th Apr 20239:08 amRNSPDMR Shareholding
31st Mar 202312:26 pmRNSPDMR Shareholding
29th Mar 202311:55 amRNSDirector/PDMR Shareholding
28th Mar 202311:28 amRNSPDMR Shareholding
27th Mar 202310:12 amRNSDirector/PDMR Shareholding
27th Mar 202310:07 amRNSDirector/PDMR Shareholding
24th Mar 202311:56 amRNSPDMR Shareholding
24th Mar 20238:59 amRNSDirector/PDMR Shareholding
22nd Mar 20239:16 amRNSPDMR Shareholding
17th Mar 20239:03 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.